The three core advantages of tesiparatide: scientific data reveals why it is popular around the world
Share
Global diabetes drug sales data for 2023 shows that tirzepatide captured 35% of the GLP-1 receptor agonist market share within just 18 months of its launch, while semaglutide's growth rate dropped to 12% during the same period. This market shift stemmed from three breakthrough advantages:
Advantage 1: Dual-target mechanism leads to better metabolic regulation
🧬 Differences in mechanism of action
|
drug |
target |
Pathway of action |
|
Smegglutide |
GLP-1 receptor monoagonal |
Only activate the glucagon-like peptide-1 pathway |
|
Tisipatide |
GIP/GLP-1 dual agonist |
Synchronous regulation of glucose-dependent insulinotropic peptides |
Clinical evidence (SURPASS-2 study):
● Blood glucose control : tesipatide 15mg group showed a 2.4% reduction in HbA1c compared to semaglutide 1mg group (1.9%).
● β-cell function : HOMA-β index improved by 68% (compared to only 41% in the Smecta group).
● 24-hour blood glucose curve : fluctuation range reduced by 35 %
Advantage 2: Excellent weight loss effect
📊 Weight loss data comparison (STEP vs SURPASS study)
|
index |
tesipatide 15mg |
Smegglutide 2.4mg |
Advantage range |
|
Weight loss in 68 weeks |
-15.6kg |
-12.4kg |
+26% |
|
Waist circumference reduction |
-12.1cm |
-9.3cm |
+30% |
|
≥15% weight loss |
52% |
36% |
+44% |
Key findings :
● Visceral fat decreased by more than 42% (MRI scan).
● Lean body mass retention rate is 3.2 percentage points higher.
● Weight plateau occurs 8-12 weeks later
Advantage 3: More comprehensive metabolic improvement
🌟 Comparison of benefits across multiple systems
1. Liver health
● Improvement rate of fatty liver: 62% vs 45% (FibroScan test)
● Decrease in ALT, a liver inflammation marker: 47% vs 32%
2. Cardiovascular protection
● Decreased systolic blood pressure: 8.2 mmHg vs 5.7 mmHg
● Improvement in arterial stiffness: CAVI index change -0.8 vs -0.3
3. Convenience of medication use
● The recommended dosage cycle is short, 2-4 weeks.
● Injection pain score is 30% lower
💡 Priority Selection Recommendations for Three Groups
1. Patients with severe insulin resistance (HOMA-IR>5)
2. A dual mechanism more effectively improves obesity in the sensitive BMI ≥ 35 population.
3. An additional 4-5 kg difference in weight loss is clinically significant in diabetic patients with fatty liver ( Liver fat content decreased by more than 17 percentage points.
🏆Asakusa Cosmetics provides you with
✔️ Authentic tesipatide (global cold chain shipping)
✔️ Hospital prescription
✔️ Online doctor consultation
✔️ Pharmacist's Medication Instructions
✔️ Comprehensive after-sales tracking service
⚠️ Friendly reminder: This article is for reference only. Please consult your doctor for specific medication advice.
---------------------------------------------------------------------------------------------------
📞Welcome to scroll down to contact customer service, purchase online, and have it shipped directly to your door.